Business
Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk
MOUNTAIN VIEW, Calif., March 24, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry.
About this update from Aditxt, Inc.
[{"type":"text","content":"Acquisition is key to Pearsanta’s mission of addressing cancer through early detection and prevention","length":101,"tagName":"p","attribs":{}},{"type":"text","content":"Pearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA/CAP-certified monitoring center and laboratories","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"MOUNTAIN VIEW, Calif., March 24, 2025--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry.","length":467,"tagName":"p"},{"type":"text","content":"Pearsanta acquired the patents in exchange for the issuance of Pearsanta Convertible Preferred Stock in a transaction valued at approximately $1 million. Over the next two to three years, Pearsanta will seek to advance clinical validation, regulatory submissions, and commercialization efforts to integrate this technology into its diagnostic portfolio.","length":353,"tagName":"p"},{"type":"text","content":"The acquisition aligns with Pearsanta’s mission to advance early cancer detection and prevention that is globally accessible. Mitomic® Technology, Pearsanta’s proprietary platform, uses mitochondrial DNA biomarkers designed for non-invasive cancer detection. With the addition of adductomics-based DNA damage analysis, Pearsanta is expanding its capabilities to assess carcinogen exposure and genomic instability before permanent mutations occur, reinforcing its commitment to proactive cancer risk assessment.","length":510,"tagName":"p"},{"type":"text","content":"Enhancing Early Cancer Detection with Adductomics","length":49,"tagName":"p"},{"type":"text","content":"The acquired patents cover proprietary advancements in DNA adduct detection and analysis, providing the capability to assess genomic instability caused by environmental toxins and metabolic byproducts. DNA adducts—chemical modifications to DNA nucleotides caused by carcinogens—are among the earliest detectable indicators of cancer risk.","length":338,"t...